PT - JOURNAL ARTICLE AU - Omar Hasan Ali AU - David Bomze AU - Lorenz Risch AU - Silvio D. Brugger AU - Matthias Paprotny AU - Myriam Weber AU - Sarah Thiel AU - Lukas Kern AU - Werner C. Albrich AU - Philipp Kohler AU - Christian R. Kahlert AU - Pietro Vernazza AU - Philipp K. Bühler AU - Reto A. Schüpbach AU - Alejandro Gómez-Mejia AU - Alexandra M. Popa AU - Andreas Bergthaler AU - Josef M. Penninger AU - Lukas Flatz TI - Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies AID - 10.1101/2020.07.21.20159244 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.21.20159244 4099 - http://medrxiv.org/content/early/2020/07/24/2020.07.21.20159244.short 4100 - http://medrxiv.org/content/early/2020/07/24/2020.07.21.20159244.full AB - Background While the pathogenesis of coronavirus disease 2019 (COVID-19) is becoming increasingly clear, there is little data on IgA response, the first line of bronchial immune defense.Objective To determine, whether COVID-19 is associated with a vigorous total IgA response and whether IgA autoantibodies are associated with complications of severe illness. Since thrombotic events are frequent in severe COVID-19 and resemble hypercoagulation of antiphospholipid syndrome (APS), our approach focused on antiphospholipid antibodies (aPL).Materials and methods In this retrospective cohort study we compared clinical data and aPL from 64 patients with COVID-19 from three independent centers (two in Switzerland, one in Liechtenstein). Samples were collected from April 9, 2020 to May 1, 2020. Total IgA and aPL were measured with FDA-approved commercially available clinical diagnostic kits.Results Clinical records of the 64 patients with COVID-19 were reviewed and divided into a cohort with mild illness (mCOVID, n=26 [41%]), a discovery cohort with severe illness (sdCOVD, n=14 [22%]) and a confirmation cohort with severe illness (scCOVID, n=24 [38%]). Severe illness was significantly associated with increased total IgA (sdCOVID, P=0.01; scCOVID, P<0.001). Total IgG levels were similar in both cohorts. Among aPL, both cohorts with severe illness significantly correlated with elevated anti-Cardiolipin IgA (sdCOVID and scCOVID, P<0.001), anti-Cardiolipin IgM (sdCOVID, P=0.003; scCOVID, P<0.001), and anti-Beta2 Glycoprotein-1 IgA (sdCOVID and scCOVID, P<0.001). Systemic lupus erythematosus was excluded from all patients as a potential confounder of APS.Conclusions Higher total IgA and IgA-aPL were consistently associated with severe illness. These novel data strongly suggest that a vigorous antiviral IgA-response triggered in the bronchial mucosa induces systemic autoimmunity.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work. Josef M. Penninger is founder and shareholder of Apeiron developing soluble ACE-2 as a COVID-19 therapy. Josef M. Penninger has no direct conflict of interest related to the paper or the data presented therein. No other relationships or activities that could appear to have influenced the submitted work were reported.Funding StatementThis submitted work was supported by grants from the Swiss National Science Foundation (grant PP00P3_157448 to Dr. Flatz, grant P400PM_194473 to Dr. Hasan Ali, and grant PZ00P3_179919 to Dr. Kohler). No other funding was received for any aspect of this submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The collection of patient data and blood samples were approved by the respective local ethics committees of the participating study centers in Switzerland and Liechtenstein (Project-IDs 2020-00676, 2020-00821, and 2020-00646)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article.